Prediabetes

This year at AACE, two studies were presented demonstrating liraglutide’s potential benefits in new patient populations. According to the studies, liraglutide appears to work both as an add-on to insulin in type 1 diabetes and as a weight-loss agent in nondiabetic patients.

Guest Editorial We are always glad to hear from our readers and recently we received this response from Alan S. Kaplan, M.D., to our March 4th Diabetes Clinical Mastery Series, Issue #178, in which we included two presentations focusing on prediabetes. We thought it was well worth sharing Dr. Kaplan’s perspective. …

A lower percentage of type 2 diabetes cases are going undiagnosed than was the case in the past couple of decades, researchers found…. 

Not only may an intensive program of diet, exercise, or both delay progression from prediabetes to diabetes, but among women, it may also lower CVD and all-cause mortality…. 

Cardiometabolic risk factors also significantly improved….

  The Diabetes Risk Test  The risk test for diabetes was developed by the American Diabetes Association to help medical professionals find those patients with prediabetes and begin early treatment and education. Every patient should have the opportunity to take this test and discuss it with their medical team. Download …

John Anderson, MD, gives us a brief introduction to himself and talks about how, as an internal medicine specialist, he deals with a whole range of issues related to diabetes which he see in his patients. More videos with John Anderson, MD: Thoughts on SGLT-2 Inhibitors What is the ADA …

John Anderson, MD, talks about the efforts of the American Diabetes Association, and how they are using the successful experiences they have gained through landmark studies such as the Diabetes Prevention Program (DPP), applying this knowledge to new initiatives such as outreach into the community through the YMCA and other …

John Anderson, MD, talks about how clinicians should look at more than just a specific A1c number when beginning treatment for diabetes explaining that the measure is really only a way to project future risk. Factors such as family history, ethnic background and other characteristics may be more relevant. But …

John Anderson, MD, talks about the new SGLT-2 inhibitors, what he has heard so far on their efficacy, and some of the concerns that have been raised about this new class of drugs…. See more SGLT-2 Resources More videos with John Anderson, MD: John Anderson, MD, ADA Board of Directors, …